About Us

Opthea Pty Ltd is a private, 100% owned subsidiary of Circadian Technologies Limited based in Melbourne, Australia.

Opthea is developing novel biologic inhibitors of angiogenesis (blood vessel growth), lymphangiogenesis (lymphatic vessel growth) and vascular leakage for the treatment of ophthalmic diseases.

Opthea has received seed funding from Circadian Technologies and is actively seeking partnership opportunities and investment for its development programs. Enquiries can be directed to: info@opthea.com


Business size

26-100 employees


Commercial presence